Bristol-Myers Squibb Company (BMY)
Operating return on assets (Operating ROA)
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Operating income | US$ in thousands | -12,554,000 | -9,290,000 | -10,290,000 | -17,133,000 | -1,416,000 |
| Total assets | US$ in thousands | 92,603,000 | 95,159,000 | 96,820,000 | 109,314,000 | 118,481,000 |
| Operating ROA | -13.56% | -9.76% | -10.63% | -15.67% | -1.20% |
December 31, 2024 calculation
Operating ROA = Operating income ÷ Total assets
= $-12,554,000K ÷ $92,603,000K
= -13.56%
The operating return on assets (operating ROA) of Bristol-Myers Squibb Company has been showing a declining trend over the years based on the provided data. Starting at -1.20% on December 31, 2020, it decreased to -15.67% by December 31, 2021, indicating a significant drop in profitability relative to its assets. Despite a slight improvement to -10.63% by December 31, 2022, the metric declined again to -9.76% by December 31, 2023. The trend continued downward, with operating ROA reaching -13.56% by December 31, 2024.
This consistent decrease in operating ROA suggests that Bristol-Myers Squibb Company is facing challenges in generating profits from its operating activities relative to the total assets employed. Further analysis of the company's operational efficiency, asset utilization, and profitability margins may be necessary to understand the underlying reasons for this decline and to identify potential areas for improvement.
Peer comparison
Dec 31, 2024